<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152005</url>
  </required_header>
  <id_info>
    <org_study_id>10-918-10</org_study_id>
    <nct_id>NCT04152005</nct_id>
  </id_info>
  <brief_title>Endothelin Concentrations in a Population With Cardiovascular Disease and Periodonitis</brief_title>
  <official_title>Analysis of Endothelin Concentrations in a Population With Cardiovascular Disease and Periodontitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Messina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, a key role played in the ethiology of periodontitis has been highlighted by a
      Endothelin (ET-1). ET1 possess the ability to express surface antigens of endothelial and
      hematopoietic stem cells and to assist in maintaining vascular integrity and the repair
      mechanism of the endothelium. ET originate from bone marrow
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present study was to investigate the association between ET-1 in patients with
      periodontitis. Furthermore, the objective was to determine if the periodontal status
      influenced ET-1 levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 25, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of ET-1 levels</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation of ET-1 levels with periodontal and cardiovascular disease</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">165</enrollment>
  <condition>Serum; Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Periodontitis</arm_group_label>
    <description>Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiovascular</arm_group_label>
    <description>Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Periodontitis+Cardiovascular</arm_group_label>
    <description>Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease</description>
    <arm_group_label>Cardiovascular</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Periodontitis</arm_group_label>
    <arm_group_label>Periodontitis+Cardiovascular</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        34 patients with CP, 34 patients with CHD, 34 patients with CP+CHD, and 34 healthy subjects
        were finally enrolled
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of at least 16 teeth

          -  CP with a minimum of 40% of sites with a clinical attachment level (CAL)

             ≥2mm and probing depth (PD) ≥4mm;

          -  Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital
             periapical radiographs

          -  Presence of ≥40% sites with bleeding on probing (BOP)

        Exclusion Criteria:

          -  Intake of contraceptives

          -  Intake of immunosuppressive or anti-inflammatory drugs throughout the last three
             months prior to the study

          -  Status of pregnancy or lactation

          -  Previous history of excessive drinking

          -  Allergy to local anaesthetic

          -  Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin,
             Nifedipine, Cyclosporin A or similar drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Matarese</last_name>
    <role>Study Director</role>
    <affiliation>University of Messina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Messina</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Messina</investigator_affiliation>
    <investigator_full_name>Gaetano Isola, DDS, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all collected IPD, all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>5 years</ipd_time_frame>
    <ipd_access_criteria>IRB university of messina</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

